There are nowadays available in most European countries for patients with stage 3 of chronic kidney disease and proteinuria more than 0.2 g/g creatinine, so SGLT2 inhibitors can be used in patients with Alport syndrome. Here, SLC5A2 is linked to chronic kidney disease.